Post by Idorsia Pharmaceuticals Ltd

Idorsia has taken an important step to strengthen its financial foundation. We have secured a senior secured term loan of up to CHF 250 million with Pharmakon – eliminating near-term debt maturities, extending our cash runway well into 2028, and increasing our financial flexibility. This milestone reflects the confidence of our partners in the strength of our business and the potential of our portfolio. As our CFO Arno Groenewoud highlights: “This transaction strengthens our balance sheet and positions us to execute with focus, accelerate growth and unlock long-term value – while maintaining strict financial discipline.” We are now better positioned to move forward with clarity and purpose. Read the media release: https://bit.ly/idiamr #Idorsia #Biotech #Healthcare #Finance #Growth #Innovation